Future Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
December 9th 2020Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.
Future Plans for the Evaluation of Ponatinib During the Ongoing OPTIC Trial
December 9th 2020Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.
Common Prior Therapies for Patients With Relapsed/Refractory Multiple Myeloma
December 9th 2020Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.
Using Belantamab Mafodotin and Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma
December 9th 2020Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
Pharmacists Can Preemptively Educate Patients on the Process for Receiving a COVID-19 Vaccine
December 7th 2020In an interview with Pharmacy Times, Stefan Behrens, PhD, CEO and co-founder of GYANT, and Justin Graham, MD, MS, chief medical officer, said preparing patients for the process of receiving a coronavirus disease 2019 (COVID-19) vaccine is essential.
The Significance of 3 New Patient Cases in Understanding Congenital Plasminogen Deficiency
December 7th 2020Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on 3 new patient cases from their presentation and the significance of these cases to their research.
Understanding Parallel Target Identification Efforts in the Induction of Fetal Hemoglobin
December 7th 2020Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what their parallel target identification efforts were able to identify, and how this identification was important in his research.
Understanding Further Treatment Opportunities for Patients With Polycythemia Vera
December 7th 2020Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the implications of the results of his research on further investigation and treatment opportunities for patients with polycythemia vera.
Understanding Causes of Death of Patients With Polycythemia Vera
December 7th 2020Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the noteworthy results observed in the study in relation to cause of death among patients with polycythemia vera.
Investigating Prior Data on the Causes of Death for Patients With Polycythemia Vera
December 7th 2020Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the issues existing around prior data on the causes of death for patients with polycythemia vera (PV) and why it was important to have greater clarity in this area.
Common Manifestations of Congenital Plasminogen Deficiency
December 6th 2020Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on the common manifestations of congenital plasminogen deficiency, and whether it is life threatening for patients.
Survival Estimates and Mortality Rates Among Patients With Polycythemia Vera
December 6th 2020Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the survival estimates for patients with polycythemia vera in the past and the mortality rates among these patients.